By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

Trodelvy showed fewer severe side effects and required fewer dose reductions or discontinuations compared to chemotherapy in TNBC patients. Common side effects, such as neutropenia and diarrhea, were ...

Triple-negative breast cancer (TNBC) lacks hormone receptors and HER2 amplification, limiting the effectiveness of targeted therapies and contributing to its aggressive clinical behavior. As aberrant ...

In what researchers are calling a potentially transformative development for breast cancer care, an experimental vaccine targeting triple-negative breast cancer (TNBC) has shown encouraging results in ...

Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC patients. The study's primary endpoint, progression-free survival, favored ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus ...